Mutation News and Research

RSS

New study sheds light on potassium pore dynamics and serves as an important foundation for research

The December 2009 issue of the Journal of General Physiology (JGP) contains a paper by Christopher Ahern (The University of British Columbia, Vancouver) and colleagues that explores pore mutation effects in Shaker and other K+ channels using in vivo nonsense suppression technology. The study will be published online November 16 (www.jgp.org).

19 Nov 2009

Why avian flu virus has not caused a pandemic?

Bird flu viruses would have to make at least two simultaneous genetic mutations before they could be transmitted readily from human to human, according to research published today in PLoS ONE.

19 Nov 2009

Diagnosing patients with syndrome similar to neurofibromatosis type 1 may be difficult

An analysis of patients with a syndrome similar to the genetic disorder, neurofibromatosis type 1, indicates that diagnosis may be difficult because of shared clinical findings, such as certain pigmentary characteristics, according to a study in the November 18 issue of JAMA.

19 Nov 2009

New biomarkers can predict patients' response to certain drugs

Recent advances in cancer therapeutics have led to the discovery of biomarkers that can predict patient response to certain drugs. Screening for mutations in the epidermal growth factor receptor (EGRF) prior to non-small cell lung cancer treatment, for example, has been shown to indentify patients who are likely to respond to treatment with erlontinib. This maximizes the drug's impact, and spares patients who are not likely to benefit from being subjected to potentially debilitating side effects.

19 Nov 2009

Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical data presented at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics shows that STA-9090, a novel, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated strong activity in multiple tumor models.

18 Nov 2009

Developmental biologists to participate in $100 million federal 'Bench to Bassinet' network

Developmental biologists at the University of Pittsburgh have been chosen to participate in a $100 million federal "Bench to Bassinet" network that is dedicated to learning about the formation of the cardiovascular system and applying that knowledge to create new diagnostic and intervention strategies for congenital heart disease.

18 Nov 2009

AACR-NCI-EORTC conference highlights major expansion in cancer drug pipeline

To highlight results of more recent research, the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Conference will host a press briefing on "Drugs in the Pipeline." Sara A. Courtneidge, Ph.D., D.Sc., professor and director of the Tumor Microenvironment Program, and director of academic affairs at the Burnham Institute for Medical Research, will moderate this press briefing.

17 Nov 2009

New Web-based application for tracking the H1N1 flu virus across the globe

New methods of studying avian influenza strains and visually mapping their movement around the world will help scientists more quickly learn the behavior of the pandemic H1N1 flu virus, Ohio State University researchers say.

17 Nov 2009

Antioxidant found in vegetables can protect cells from damage caused by infection and injury

Scientists at the University of Pennsylvania School of Medicine discovered that a dietary antioxidant found in such vegetables as broccoli and cauliflower protects cells from damage caused by chemicals generated during the body's inflammatory response to infection and injury. The finding has implications for such inflammation-based disorders as cystic fibrosis (CF), diabetes, heart disease, and neurodegeneration.

17 Nov 2009

Determining the cause for death of photoreceptors could hold the key to stopping blinding disorders

Determining what triggers the death of retinal cells, called photoreceptors, could hold the key to stopping blinding disorders caused by a wide range of eye diseases, Yale School of Medicine researchers report in the November journal Investigative Ophthalmology & Visual Science.

16 Nov 2009

Genetic test for familial Dilated Cardiomyopathy launched by PGxHealth

PGxHealth, a division of Clinical Data, Inc., today announced the launch of its genetic test for familial Dilated Cardiomyopathy, an inherited heart disease which is the leading cause of heart transplants and a possible cause of sudden cardiac death.

16 Nov 2009

Postmortem genetic testing to identify genetic mutations after SUD effective in identifying risk

Targeted postmortem testing to identify genetic mutations associated with sudden unexplained death (SUD) is an effective and less expensive way to determine risk to relatives than comprehensive cardiac testing of first degree relatives, according to research presented at the American Heart Association's Scientific Sessions 2009.

16 Nov 2009

Cytoskeleton plays a critical role to bring chromosome pairs together: Study

Meiosis - the pairing and recombination of chromosomes, followed by segregation of half to each egg or sperm cell - is a major crossroads in all organisms reproducing sexually. Yet, how the cell precisely choreographs these chromosomal interactions is a long-standing question.

16 Nov 2009

Scientists to develop a treatment for rare genetic disorder, FOP

An international team of scientists, led by researchers at the University of Pennsylvania School of Medicine, is taking the first step in developing a treatment for a rare genetic disorder called fibrodysplasia ossificans progressiva (FOP), in which the body's skeletal muscles and soft connective tissue turns to bone, immobilizing patients over a lifetime with a second skeleton.

13 Nov 2009

New gene therapy may breach the armor of cancerous tumors

The seeming invincibility of cancerous tumors may be crumbling, thanks to a promising new gene therapy that eliminates the ability of certain cells to repair themselves. Researchers at the Cornell University College of Veterinary Medicine have discovered that inactivation of a DNA repair gene called Hus1 efficiently kills cells lacking p53 -- a gene mutated in the majority of human cancers.

13 Nov 2009

New findings on human genome may be useful for developing specific AIDS drugs

The AIDS virus inserts its genetic material into the genome of the infected cell. Scientists of the German Cancer Research Center have now shown for the first time that the virus almost entirely spares particular sites in the human genetic material in this process. This finding may be useful for developing new, specific AIDS drugs.

13 Nov 2009

AvidBiotics granted U.S. and European patents concerning its DGR technology platform

AvidBiotics Corp. announced the issuance of foundational patents encompassing a completely novel mechanism for generating massive diversity within precisely targeted sites of protein-encoding DNA sequences. The technology platform is referred to as Diversity Generating Retroelements (DGR) and patents were issued in both the United States (#7,585,957) and in Europe (#1,173,995). UCLA and AvidBiotics Corp are co-assignees of the patents, and AvidBiotics holds exclusive, worldwide rights to the patents from UCLA.

13 Nov 2009

Cequent Pharmaceuticals proposes the first test of an orally administered RNA interference drug in humans

Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, has announced that it has filed its first IND (investigational new drug) application with the U.S. Food and Drug Administration (FDA).

12 Nov 2009

Update on Alnylam Pharmaceuticals' RNAi pipeline, platform, and technology

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, is providing an update on its RNAi pipeline, platform, and technology at its R&D Day being held in New York today.

12 Nov 2009

Stapled Peptides directly inhibit the Notch transcription factor complex

Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, “Direct Inhibition of the Notch Transcription Factor Complex.”

12 Nov 2009

Mutation News and Research

New study sheds light on potassium pore dynamics and serves as an important foundation for research

Why avian flu virus has not caused a pandemic?

Diagnosing patients with syndrome similar to neurofibromatosis type 1 may be difficult

New biomarkers can predict patients' response to certain drugs

Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented

Developmental biologists to participate in $100 million federal 'Bench to Bassinet' network

AACR-NCI-EORTC conference highlights major expansion in cancer drug pipeline

New Web-based application for tracking the H1N1 flu virus across the globe

Antioxidant found in vegetables can protect cells from damage caused by infection and injury

Determining the cause for death of photoreceptors could hold the key to stopping blinding disorders

Genetic test for familial Dilated Cardiomyopathy launched by PGxHealth

Postmortem genetic testing to identify genetic mutations after SUD effective in identifying risk

Cytoskeleton plays a critical role to bring chromosome pairs together: Study

Scientists to develop a treatment for rare genetic disorder, FOP

New gene therapy may breach the armor of cancerous tumors

New findings on human genome may be useful for developing specific AIDS drugs

AvidBiotics granted U.S. and European patents concerning its DGR technology platform

Cequent Pharmaceuticals proposes the first test of an orally administered RNA interference drug in humans

Update on Alnylam Pharmaceuticals' RNAi pipeline, platform, and technology

Stapled Peptides directly inhibit the Notch transcription factor complex

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News